COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter?Article Published on 2021-10-092022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] age all age group Attitudes conducted COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional survey Effect experience expressed females Gender group injection less lower risk majority Malaysia male occurred Oxford-AstraZeneca participant perceptions Pfizer-BioNTech positive Prevalence Program receiving Registered reported second dose side Side effect Side effects Sinovac tiredness Twenty participant Type vaccinated individual Vaccinations Vaccine [DOI] 10.3390/vaccines9101156 PMC 바로가기 [Article Type] Article
Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy임신 중 산모의 SARS-CoV-2 불활성 백신(CoronaVac) 투여 후 제대혈 항체Article Published on 2021-10-032022-09-11 Journal: Human vaccines & immunotherapeutics [Category] SARS, 치료기술, [키워드] administration adverse event adverse events age anti-RBD anti-receptor-binding domain antibodies antibody arbitrary unit Beijing Birth Birth weight Blood Care China Cord blood CoronaVac detectable Efficacy first dose first identified case gestation gestational age HCW Health Health care healthy IgG antibodies inactivated inactive life Maternal mother Newborn placental Pregnancy RBD reported SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 vaccines Science second dose sera Sinovac Spike protein the vaccine transfer vaccination Vaccine virus [DOI] 10.1080/21645515.2021.1947099 PMC 바로가기 [Article Type] Article
CoronaVac (Sinovac) COVID-19 vaccine-induced molecular changes in healthy human serum by infrared spectroscopy coupled with chemometricsArticle Published on 2021-08-302022-10-29 Journal: Turkish Journal of Biology [Category] COVID-19, [키워드] addition administration Attenuated total reflection-Fourier Transform Infrared (ATR-FTIR) caused changes in CoronaVac CoronaVac-Sinovac coronavirus COVID-19 COVID-19 vaccine deaths determine Fourier Transform Infrared (FTIR) spectroscopy functional group healthy human serum inactivated Linear Discriminant Analysis lipids molecular Multivariate analysis nucleic acids outcome pandemic PCA principal component analysis Protein separated serum significant changes in Sinovac the disease the vaccine vaccination Vaccine [DOI] 10.3906/biy-2105-65 PMC 바로가기 [Article Type] Article
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case reportCase Report Published on 2021-08-122022-10-29 Journal: The Journal of Headache and Pain [Category] Coronavirus, MERS, SARS, [키워드] ARMS Aspirin BMI Brain Case report conducted CoronaVac CoronaVac vaccine cortical Cortical spreading depression COVID COVID-19 CT scan Depression diffusion discharged evaluate Evidence female functional Headaches Infarction legs literature review mimicking moderate MRC MRI Neurological deficit Patient performed Physical examination receiving Sinovac stroke suffered Treatment unlikely vaccination vital sign was done was performed weakness [DOI] 10.1186/s10194-021-01311-w PMC 바로가기 [Article Type] Case Report
Operation Warp Speed: implications for global vaccine securityOperation Warp Speed: 글로벌 백신 보안에 미치는 영향Review Published on 2021-07-012022-09-11 Journal: The Lancet. Global health [Category] 신약개발, 임상, [키워드] AstraZeneca clinical testing COVID-19 COVID-19 vaccines develop Efficacy effort Emergency use equity Expanded access funding global effort group Health implication Informed consent Interim analyses interim analysis Johnson & Johnson Johnson & Johnson Justice mechanism Microbiology Moderna nine Novavax operation Pfizer Phase 3 populations provided question Sinopharm Sinovac speed transition Vaccine [DOI] 10.1016/S2214-109X(21)00140-6 PMC 바로가기 [Article Type] Review
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trialSARS-CoV-2 백신(비활성화, Vero 세포)의 효능과 안전성을 평가하기 위한 무작위 이중 맹검 위약 대조 임상 3상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-132022-09-10 Journal: Trials [Category] MERS, SARS, 비임상, 임상, 치료기술, [키워드] 1:1 24 hour 24 hours 95% confidence interval Activation Active surveillance administration Administrative Personnel Adverse adverse event adverse events Adverse reaction Adverse reactions African green monkey age Algorithm Aluminium aluminium hydroxide anaphylaxis Antibody test Antibody titer Antigen Arm asplenia assigned assumed assumption Autoimmune baseline bleeding disorders Blinding blood product blood products blood sample Blood samples breastfeeding women breath carried Cell culture China chloride Clinical efficacy clinical trial code Cohort cohorts comparator consent form cooperation Corticosteroid Corticosteroids COVID-19 COVID-19 cases COVID-19 disease COVID-19 symptoms COVID-19 test criteria Critical CRO Data and Safety Monitoring Board Day development diary dihydrogen DIHYDROGEN PHOSPHATE disease disodium disodium hydrogen phosphate dissemination dose dose of vaccination double blind double-blind double-blind study Efficacy Efficacy and safety element eligible Endpoint enrolled enrolment ethics committee evaluate event excluded exclusion criteria expected Follow-up follow-up period Frequency Gender genders green monkey group groups healthcare Healthcare professional healthcare professionals higher risk HIV infection hospital Hospitalization hydrogen Hydrogen phosphate hydroxide hypersensitivity identity IgG level IgG levels IgG test immunogenicity Immunoglobulin immunoglobulins immunosuppressive immunosuppressive therapy inactivated Inactivated Vaccines incidence incidence rate include Inclusion individual information informed consent form initiated Interactive Web Response System intramuscular dose investigator IWRS IWRS system kidney knowledge Local local reactions management medical doctors medical emergency Ministry of Health mortality rates neutralizing antibody Neutralizing antibody titer Novel coronavirus number Nurses objective Omega Other participant PCR PCR positivity performed Phase III Clinical Trial phosphate Placebo placebo group placebo-controlled positive pregnancy test pregnant preparation primary efficacy endpoint professional proportion protocol randomised randomised controlled trial randomised placebo controlled trial randomization Randomized Randomly Reactions receive recorded regimens Registration reported response risk risk of infection RT-PCR RT-PCR test RT-PCR tests Safety Monitoring Board Sample size SARS-CoV-2 vaccine SARS-CoV-2 virus screened second dose secondary Secondary objectives Serious Adverse Event Serious Adverse Events seroconversion rate Seropositivity severity severity of COVID-19 shown Sinovac sodium Sodium chloride sodium dihydrogen phosphate Sponsor status study group Study protocol subject subject’ supplementary material Symptom symptomatic symptomatic case symptomatic cases System systemic adverse reaction the ethics committee the timing the vaccine therapy Treatment treatment arm Trial Turkey two-sided vaccinated groups vaccination Vaccine Vero Vero Cell Web website width with COVID-19 within 6 months [DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter
Mini-Review Discussing the Reliability and Efficiency of COVID-19 VaccinesReview Published on 2021-03-242022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] administration Adverse reactions affected age age and sex All adverse event alleviate approved article beta-coronavirus conducted coronavirus 2 COVID-19 database death develop died dose-dependent drug Effect Efficacy Efficacy and safety Evidence FIVE form Frequency individual Johnson & Johnson manuscript Mild Moderna Pfizer–BioNTech produced ranged recipient recipients reported respiratory Safe Safety SARS-CoV-2 searched severe adverse reactions Sex Side effects Sinopharm Sinovac the patient Vaccine Vaccines [DOI] 10.3390/diagnostics11040579 PMC 바로가기 [Article Type] Review
A review of the genome, epidemiology, clinical features, prevention, and treatment scenario of COVID-19: Bangladesh aspectsReviews Published on 2021-01-292022-10-31 Journal: The Egyptian Journal of Bronchology [Category] COVID-19, [키워드] acute respiratory disease age Bangladesh aspects candidate vaccine caused China clinical feature Clinical features clinical trial coronavirus country COVID-19 COVID-19 patient death Deceased development Diagnosis dry cough economic impact Epidemiology European fatigue female Fever Gender Genome Haplotype Health healthcare facility highest homology immune system implicated IMPROVE Incubation period individual Isolation lockdown lower mortality mortality rate ORF1ab gene pandemic Patient patients Phylogenetic analysis prevalent preventive measure promote quarantine reflect SARS-CoV-2 sequence single-nucleotide Sinovac social distancing susceptible the N protein Treatment Vaccine development variant variants virus virus strain [DOI] 10.1186/s43168-021-00053-2 PMC 바로가기 [Article Type] Reviews
Direct from the COVID-19 crisis: research and innovation sparks in BrazilCommentary Published on 2021-01-212022-10-31 Journal: Health Research Policy and Systems [Category] COVID-19, [키워드] approved Arm Brazil carried category collected data conducted coronavirus disease country Coverage COVID-19 deaths diagnostic tests Direct disease dose education effective Emergency use Ethics examined foundation Health Health economic-industrial complex health emergency include infecting knowledge mechanism Medicine MOST organized Oxford pandemic performed Personal protective equipment PROTECT public health recorded reduce reported Research Research innovation and development Result Safe Scientific community Sinovac Spread transfer Trial trials university vaccination Vaccine Vaccines Volunteer website [DOI] 10.1186/s12961-020-00674-x PMC 바로가기 [Article Type] Commentary
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial이중 맹검, 무작위, 위약 대조 임상 3상 임상 시험을 통해 의료 전문가를 Sinovac에서 제조한 흡착된 COVID-19(불활성화) 백신으로 치료하는 효과와 안전성을 평가합니다. – PROFISCOV: 무작위 대조를 위한 연구 프로토콜의 구조화된 요약 재판Letter Published on 2020-10-152022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 95% confidence interval Active surveillance adjuvant Administered administration Adults adverse event adverse events Adverse reaction Adverse reactions age Aluminium aluminium hydroxide Analysis attack rate Beijing blind Blinding Brazil Breastfeeding calculated Care causal relationship China clinical clinical care clinically Committee completion confirmed case Consent consent form Contact contact with Control COVID-19 criterion database defined Diagnosis direct contact disease dissemination dose double-blind double-blind study Efficacy Efficacy and safety elderly element Endpoint evaluate exclusion criteria expected experimental intervention FDA form Frequency genders Health Health Organization hydroxide immunogenicity inactivated Inactivated Vaccines incidence include Inclusion information Informed intramuscular dose life limit Local monitoring multicenter nucleic acid number Nurse Nurses objective Occurrence Older outcome participant Participants Participation Patient phase Phase III Clinical Trial Placebo placebo-controlled clinical trial pregnant pregnant women primary efficacy endpoint produced product professional professionals protocol randomisation randomised randomised controlled trial randomization randomization list randomization system Randomized receive recruitment regimen registry responsible retained Safety Sample size SARS-CoV-2 nucleic acid SARS-CoV-2 virus schedule second vaccination separation Sinovac Sinovac Life Science Sinovac Life Sciences Sponsor status stratified Study protocol subjects symptomatic case symptomatic cases symptomatic individuals systemic adverse reaction systemic adverse reactions the vaccine threshold Trial Trial registration undergo vaccination Vaccine Virological voluntary website World Health Organization [DOI] 10.1186/s13063-020-04775-4 PMC 바로가기 [Article Type] Letter